

## TILCOTIL®

---

### 1. Product Name

---

Tilcotil 20 mg film-coated tablets.

---

### 2. Qualitative and Quantitative Composition

---

Each film-coated tablet contains 20 mg of tenoxicam.

Excipient with known effect: Lactose

Allergen Declaration: Sugars as lactose

For the full list of excipients, see section 6.1.

---

### 3. Pharmaceutical Form

---

Tilcotil are greyish yellow, oval, cylindrical, biconvex film-coated tablets with the imprint "20" on one side and a break-score on the other side.

The tablet can be divided into equal doses.

---

### 4. Clinical Particulars

---

#### 4.1 *Therapeutic indications*

Tilcotil is indicated for the symptomatic treatment of the following painful inflammatory and degenerative disorders of the musculoskeletal system:

- rheumatoid arthritis;
- osteoarthritis;
- arthrosis;
- ankylosing spondylitis;
- extra-articular disorders, e.g. tendinitis, bursitis, periarthrosis of shoulders (shoulder-hand syndrome) or hips, strains and sprains;
- post-operative pain;
- acute gout;
- primary dysmenorrhea.

#### 4.2 *Dose and method of administration*

##### **Dose**

##### **Adults**

Undesirable effects may be minimised by using the lowest effective dose for the shortest possible duration necessary to control symptoms.

---

For all indications except primary dysmenorrhoea, post-operative pain and acute gout, a daily dosage of 20 mg should be given at the same time of day.

The recommended dose for primary dysmenorrhoea is 20 to 40 mg once daily.

For post-operative pain the recommended dose is 40 mg once daily up to five days.

For acute attacks of gout the recommended dose is 40 mg once daily for two days followed by 20 mg once daily for a further five days.

In treatment of chronic disorders, the therapeutic effect of tenoxicam is evident early in treatment and there is a progressive increase in response over time. In chronic disorders, daily doses higher than 20 mg are not recommended since this would increase the frequency and intensity of unwanted reactions without significantly increasing efficacy.

For patients needing long-term treatment a reduction to a daily oral dose of 10 mg may be tried for maintenance.

### ***Special populations***

#### **Elderly**

The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for gastrointestinal (GI) bleeding during NSAID therapy.

#### **Renal impairment**

In principle, the above dosage recommendations also apply to patients suffering from kidney or liver disease. Dosage should be minimised in patients with renal impairment.

#### **Paediatric**

No dosage recommendations have been established for children and adolescents due to insufficient data.

### **Method of administration**

The tablets should be taken with a glass of water. It is preferable to take this medicine during or immediately after a meal.

## **4.3 Contraindications**

- Hypersensitivity to tenoxicam, or to any of the excipients listed in section 6.1; or to other non-steroidal anti-inflammatory drugs (NSAIDs).
- Asthma, or in patients whom salicylates or other NSAIDs induce symptoms of asthma, rhinitis or urticaria.
- Active or history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
- Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
- Haemorrhagic diathesis, as with other NSAIDs.
- Severe renal, hepatic or heart failure, as with other NSAIDs.
- During the third trimester of pregnancy (see section 4.6).

## **4.4 Special warnings and precautions for use**

Tenoxicam is relatively contraindicated in patients with liver dysfunction.

The use of tenoxicam with concomitant NSAIDs, including cyclo-oxygenase-2 selective inhibitors should be avoided.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2).

### ***Cardiovascular and/or cerebrovascular effects***

Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.

Clinical trial and epidemiological data suggest that use of selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) and some NSAIDs (particularly at high doses and long term treatment) may be associated with a small increased risk of arterial thrombotic events, including myocardial infarction and stroke. Patients with cardiovascular disease or cardiovascular risk factors may also be at greater risk.

Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with tenoxicam after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).

To minimise the potential risk of an adverse cardiovascular event in patients taking an NSAID, especially in those with cardiovascular risk factors, the lowest effective dose should be used for the shortest possible duration (see section 4.2).

NSAIDs may lead to the onset of new hypertension or worsening of pre-existing hypertension and patients taking anti-hypertensives with NSAIDs may have an impaired anti-hypertensive response.

Caution is advised when prescribing NSAIDs to patients with hypertension. Blood pressure should be monitored closely during initiation of NSAID treatment and at regular intervals thereafter.

Fluid retention and oedema have been observed in some patients taking NSAIDs; therefore, caution is advised in patients with fluid retention or heart failure.

There is no consistent evidence to suggest that concurrent use of aspirin mitigates the possible increased risk of serious cardiovascular thrombotic events associated with NSAID use.

### ***Gastrointestinal bleeding, ulceration and perforation***

GI bleeding, ulceration and perforation, which can be fatal, has been reported with all NSAIDs, including tenoxicam therapy. These effects can occur at any time during treatment, with or without warning symptoms, or a previous history of serious GI events. Studies have not identified any subset of patients not at risk of developing peptic ulcer and bleeding.

Upper gastrointestinal ulcers, gross bleeding or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 - 6 months and in about 2 - 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious gastrointestinal event at some time during the course of therapy. However, even short term therapy is not without risk.

Caution is advised in patients with risk factors for gastrointestinal events who may be at greater risk of developing serious gastrointestinal events e.g. the elderly, those with a history of serious gastrointestinal events, smoking and alcoholism.

The elderly have an increased frequency of adverse reactions, to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. Debilitated patients do not seem to tolerate ulceration or bleeding as well as others. Most of the fatal gastrointestinal events associated with NSAIDs occurred in the elderly and/or debilitated patients. The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3) and in the elderly.

Patients with risk factors should commence treatment on the lowest dose possible. Combination therapy with protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these patients, and also for patients requiring concomitant low dose aspirin or other medications likely to increase gastrointestinal risk (see section 4.5).

NSAIDs should be given with care to patients with a history of inflammatory bowel disease (ulcerative colitis; Crohn's disease) as their condition may be exacerbated. Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment. If peptic ulceration or gastrointestinal bleeding occurs, tenoxicam should be withdrawn immediately. Physicians should warn patients about the signs and symptoms of serious gastrointestinal toxicity.

Caution is advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants (e.g. warfarin), selective serotonin-reuptake inhibitors or anti-platelet agents (e.g. aspirin). The concurrent use of aspirin and NSAIDs also increases the risk of serious gastrointestinal adverse events (see section 4.5).

### ***Skin reactions***

Life-threatening cutaneous reactions such as exfoliative dermatitis, toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), which can be fatal and occur without warning, have been reported with tenoxicam. These serious adverse effects are idiosyncratic and are independent of dose or duration of use.

Patients should be advised of the signs and symptoms of serious skin reactions and monitored closely for skin reactions. The highest risk of occurrence of SJS or TEN is within the first weeks of treatment.

If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, tenoxicam should be discontinued. The best results for managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspected medication. Early withdrawal is associated with a better prognosis.

If the patient has developed SJS or TEN with the use of tenoxicam, tenoxicam must not be re-started in this patient at any time.

### ***Haematological effects***

Tenoxicam inhibits platelet aggregation and may affect haemostasis. Tenoxicam has no significant influence on blood coagulation factors, coagulation time, prothrombin time or activated thromboplastin time.

Patients having coagulation disorders or receiving medication therapy that interferes with haemostasis should, however, be carefully observed when tenoxicam is administered.

### ***Ocular effects***

Adverse eye findings have been reported with NSAIDs including tenoxicam. Thus, ophthalmic evaluation is recommended for patients who develop visual disturbances.

### ***Antipyretic effects***

As known for other anti-inflammatory medicines, tenoxicam may mask the usual signs of infection.

### ***Galactose intolerance***

As Tilcotil contains lactose, patients with rare hereditary problems of galactose intolerance, the lactase deficiency or glucose-galactose malabsorption should not take this medicine.

## **Renal impairment**

NSAIDs inhibit renal prostaglandin synthesis and consequently may have an undesirable effect on renal haemodynamics and on salt and water balance. It is necessary to adequately monitor the patient with a special emphasis on cardiac and renal function (BUN, creatinine, development of oedema, weight gain, etc.) when giving tenoxicam to patients with conditions that could increase their risk of developing renal failure, such as pre-existing renal disease, impaired renal function in diabetics, hepatic cirrhosis, congestive heart failure, volume depletion or concomitant treatment with potentially nephrotoxic medicines, diuretics and corticosteroids. This group of patients is at special risk in peri- and post-operative phases of major surgery due to the possibility of serious blood loss. They therefore require close monitoring in the post-operative and recovery periods.

Because of the high plasma protein binding of tenoxicam, caution is required when plasma albumin levels are markedly reduced.

## **4.5 Interaction with other medicines and other forms of interaction**

### **Acetylsalicyclate and salicyclates**

Salicylates increase the clearance and volume of distribution of NSAIDs including tenoxicam and decrease the mean minimum steady-state plasma concentrations of tenoxicam by the competition on plasma protein binding sites. Concurrent treatment with salicylate or other NSAIDs is not recommended because of increased risk of undesirable reactions.

### **Anti-platelet agents and selective serotonin reuptake inhibitors**

There is an increased risk of gastrointestinal bleeding when anti-platelet agents and selective serotonin-reuptake inhibitors (SSRIs) are combined with NSAIDs (see section 4.4).

### **Methotrexate**

The co-administration of some NSAIDs and methotrexate has been associated with reduced renal tubular secretion of methotrexate, higher plasma concentrations of methotrexate, and severe methotrexate toxicity. Therefore, caution should be exercised when tenoxicam is administered concurrently with methotrexate.

### **Lithium**

As tenoxicam may decrease the renal clearance of lithium, their concomitant administration may lead to increased plasma levels and toxicity of lithium. The plasma levels of lithium should be closely monitored.

### **Diuretics**

As with NSAIDs in general, tenoxicam should not be administered concurrently with potassium sparing diuretics. There is a known interaction between these two classes of compounds, which may cause hyperkalaemia and renal failure.

No clinically significant interaction between tenoxicam and furosemide was noted, but tenoxicam attenuates the blood pressure lowering effect of hydrochlorothiazide.

### **Antihypertensives**

As known from other NSAIDs, tenoxicam might attenuate the antihypertensive effects of alpha-adrenergic blockers, beta-adrenergic blockers and ACE-inhibitors.

There was no clinically relevant interaction when tenoxicam was administered together with atenolol.

### **Cardiac Glycosides**

During clinical trials no interaction was reported for patients treated concomitantly with digitalis products. Thus concurrent dosing of tenoxicam and digoxin appears to be without major risk.

### ***Antacids and H<sub>2</sub>-receptor antagonists***

No clinically relevant interaction has been found with concomitantly administered antacids and cimetidine at the recommended dosages.

### ***Probenecid***

Co-administration of probenecid and tenoxicam treatment may increase plasma concentration of tenoxicam. The clinical significance of this observation has not been established.

### ***Anticoagulants***

No clinically relevant interaction has been found with concomitantly administered warfarin and phenprocoumon, and low molecular weight heparin at the recommended dosages. Nevertheless, as for other NSAIDs, careful monitoring is recommended when patients concomitantly receive anticoagulants.

### ***Oral antidiabetics***

The clinical effect of the oral antidiabetic medicines glibornuride, glibenclamide and tolbutamide was likewise not modified by tenoxicam. Nevertheless, as for other NSAIDs, careful monitoring is recommended when patients concomitantly receive oral antidiabetic medications.

### ***Colestyramine***

Colestyramine may increase the clearance and reduce the half-life of tenoxicam.

### ***Dextromethorphan***

The concomitant administration of tenoxicam and dextromethorphan may increase the analgesic effect compared to monotherapy.

### ***Ciclosporin***

Increased risk of nephrotoxicity.

### ***Alcohol***

There is no significant pharmacodynamic interaction between tenoxicam and alcohol.

### ***Food***

The extent of absorption of tenoxicam is not influenced by food, but the rate of absorption ( $C_{max}$ ) may be slower than in the fasting state.

## ***4.6 Fertility, pregnancy and lactation***

### ***Pregnancy***

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of congenital and cardiac malformation and gastroschisis after use of NSAID in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, tenoxicam should not be given unless the expected benefits to the mother outweigh the risks to the foetus. If there is a compelling need for NSAID treatment by a woman attempting to conceive, or during the first and second trimester of pregnancy, limit use to the lowest effective dose and shortest duration possible.

Tenoxicam is contraindicated in third trimester of pregnancy.

Use of NSAIDs in the second or third trimester may cause foetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Oligohydramnios is generally seen after days to weeks of treatment, although it has been reported as soon as 48 hours after NSAID initiation. Oligohydramnios is usually, but not always, reversible after treatment discontinuation. Consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours. Discontinue treatment with tenoxicam if oligohydramnios occurs.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may lead to:

- cardiopulmonary toxicity (with premature closure of the foetal ductus arteriosus and pulmonary hypertension)
- Foetal renal impairment, which may progress to renal failure with oligohydramnios
- Inhibition of platelet aggregation, and may delay labour and birth.

And the mother and the neonate, at the end of pregnancy, to:

- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
- inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently, tenoxicam is contraindicated during the third trimester of pregnancy.

## **Breastfeeding**

Based on findings from single dose administration, a very small amount (mean value less than 0.3% of the dose) of tenoxicam passes into breast milk (see section 5.2).

There is no evidence of adverse reactions in breastfed infants of mothers taking tenoxicam. Nevertheless, infants should be weaned or the medicine discontinued.

## **Fertility**

The use of tenoxicam, as with any medication known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or are undergoing investigation of infertility, withdrawal of tenoxicam should be considered.

### **4.7 Effects on ability to drive and use machines**

Patients experiencing adverse events that might affect driving or using machines, such as vertigo, dizziness or visual disturbances should refrain from driving a car or using machines.

### **4.8 Undesirable effects**

Based on clinical trials including large numbers of patients, tenoxicam proved to be well tolerated in the recommended dose. Usually the undesirable effects reported were mild and transient. In a small proportion of patients the interruption of treatment due to undesirable effects was necessary.

The most commonly observed adverse events in association with NSAIDs are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease (see section 4.4) have been reported following NSAIDs administration. Less frequently, gastritis has been observed.

Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories:

Very Common:	≥1/10
Common:	≥1/100 to <1/10
Uncommon:	≥1/1,000 to <1/100
Rare:	≥1/10,000 and <1/1,000

Very rare: <1/10,000  
 Not known: cannot be estimated from the available data.

<b>System Organ Class</b>	<b>Common ≥1/100 to &lt;1/10</b>	<b>Uncommon ≥1/1,000 to &lt;1/100</b>	<b>Rare ≥1/10,000 to &lt;1/1,000</b>	<b>Very rare &lt;1/10,000</b>	<b>Not known</b>
Blood and lymphatic system disorders					Anemia Agranulocytosis Leucopenia Thrombocytopenia
Immune system disorders					Hypersensitivity reactions (such as dyspnoea, asthma, anaphylactic reactions, angioedema)
Metabolism and nutrition disorders		Decreased appetite			
Psychiatric disorders		Sleep disorder			Confusional state Hallucinations
Nervous system disorders	Dizziness Headache				Paraesthesia Somnolence
Eye disorders					Visual disturbances (such as visual impairment and vision blurred)
Ear and labyrinth disorders		Vertigo			
Cardiac disorders		Palpitations			Cardiac failure
Vascular disorders					Hypertension Vasculitis
Gastrointestinal disorders	Gastric, epigastric and abdominal pain Dyspepsia Nausea	Gastrointestinal haemorrhages (including haematemesis and melena) Gastrointestinal ulcers Constipation Diarrhoea Vomiting Mouth ulceration Gastritis Dry mouth		Pancreatitis	Gastrointestinal perforation Exacerbation of colitis and Crohn's disease Flatulence
Hepatobiliary disorders		Increased hepatic enzymes			Hepatitis
Skin and subcutaneous tissue disorders		Pruritus Erythema Exanthema Rash Urticaria		Stevens-Johnson syndrome Toxic epidermal necrolysis	Photosensitivity reaction Fixed eruption

System Organ Class	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1,000	Very rare <1/10,000	Not known
Renal and urinary disorders		Increased blood urea or creatinine			
Reproductive system and breast disorders					Female infertility*
General disorders and administration site conditions		Fatigue Oedema			

\* Isolated cases of female infertility have been reported with medications known to inhibit cyclooxygenase/prostaglandin synthesis including tenoxicam.

Clinical trial and epidemiological data suggest that use of selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) and some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Although tenoxicam has not been shown to increase thrombotic events such as myocardial infarction, there are insufficient data to exclude such a risk with tenoxicam.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>.

## 4.9 Overdose

### Symptoms

In general, patients with a NSAID overdose are asymptomatic. NSAID overdose causes only minor CNS or gastrointestinal disturbances. There have been isolated reports of more serious toxicity after ingestion of substantial quantities; they include seizures, coma and renal failure, and cardiorespiratory arrest may occur. Hepatic dysfunction, hypothermia and metabolic acidosis are also reported.

### Treatment

In case of overdose appropriate supportive treatment is indicated and discontinuation of the medicine, antacids and proton-pump inhibitors may be indicated. There are no specific antidotes. Dialysis does not significantly clear NSAIDs from the blood stream.

For risk assessment and advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764 766).

## 5. Pharmacological Properties

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antirheumatic, anti-inflammatory and analgesic agent. ATC code: M01AC02

## Mechanism of action

The active ingredient of Tilcotil, tenoxicam, is a NSAID with anti-inflammatory, analgesic, antipyretic properties and it also inhibits platelet aggregation. Tenoxicam inhibits prostaglandin biosynthesis by inhibition of cyclooxygenase 1 (COX-1) and 2 (COX-2), both *in vitro* (sheep seminal vesicles) and *in vivo* (protection of arachidonic acid-induced toxicity in mice).

*In vitro* investigation on cyclo-oxygenase isoenzymes prepared from human COS-7 cells have shown that tenoxicam inhibits COX-1 and COX-2 isoenzymes approximately to the same extent i.e. COX-2/COX-1 ratio equals to 1.34.

*In vitro* tests of leukocyte peroxidase suggest that tenoxicam may act as a scavenger for active oxygen at the site of inflammation.

Tenoxicam is a potent *in vitro* inhibitor of human metalloproteinases (stromelysin and collagenase) which induce cartilage breakdown.

A further possible mechanism of action is the reduction of nitrite levels indicating an alteration of NO pathways.

These pharmacological effects explain, at least in part, the therapeutic benefit of tenoxicam in the treatment of painful inflammatory and degenerative disorders of the musculoskeletal system.

## Clinical / Efficacy Studies

The clinical efficacy of tenoxicam is proven in clinical studies for:

Rheumatoid arthritis: It was shown that a dose of 20 or 40 mg once daily was effective and the effect was maintained for up to two years.

Osteoarthritis: Tenoxicam is effective in the treatment of osteoarthritis. Anti-inflammatory and analgesic effects have been maintained for up to three years.

Ankylosing spondylitis: Clinical studies showed that tenoxicam is effective in the relief of pain and inflammation comparable to piroxicam.

Extra-articular disorders: Tenoxicam (20 mg once daily) was at least as effective as piroxicam (20 mg daily) and diclofenac (75 mg daily). Tenoxicam was better tolerated than diclofenac.

Acute gout: The database is small, but all available studies indicate that tenoxicam is effective in the treatment of acute gout reducing pain and inflammation. The effect is at least in part dose dependent.

Post-operative pain: It was demonstrated in placebo-controlled studies that treatment with tenoxicam is effective.

Primary dysmenorrhoea: In controlled clinical studies tenoxicam showed that the substance is effective relieving dysmenorrhoeic pain. The effect increased with time. Tenoxicam was at least as effective as ibuprofen, a standard medicinal product for the treatment of primary dysmenorrhoea.

## 5.2 Pharmacokinetic properties

### Absorption

Oral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%), whereas absorption after rectal administration is approximately 80%. Peak plasma concentrations following an oral or rectal administration are reached within two hours in fasting subjects. When taken with a meal, tenoxicam is absorbed to the same extent but the time to reach peak concentration is delayed.

With the recommended dosage regimen of 20 mg once daily, steady-state conditions are reached within ten to fifteen days without unexpected accumulation. The average concentration at steady

state is 11 mg/L when tenoxicam is given at oral doses of 20 mg once daily and this does not change even on treatment for up to four years.

As predicted from single dose kinetic, plasma concentrations at steady state are 6-fold higher than those reached after a single dose.

### **Distribution**

During the first two hours following intravenous administration of tenoxicam, plasma levels of the medicine decline rapidly.

After this short period, no difference in plasma concentrations between intravenous and oral dosing are seen. The mean volume of distribution at steady state is 10 to 12 L.

In the blood over 99% of the medicine is bound to albumin. Tenoxicam penetrates well into the synovial fluid. Peak concentrations are reached later than in plasma.

Based on findings from single dose administration a very small amount (mean value less than 0.3% of the dose) of tenoxicam passes into breast milk (see section 4.6).

### **Biotransformation**

Tenoxicam is excreted after virtually complete biotransformation to pharmacologically inactive metabolites.

### **Elimination**

Up to two thirds of an oral dose is excreted in the urine (mainly as the inactive 5'-hydroxy-tenoxicam) and the rest via the bile (a significant portion in the form of glucuronidated compounds). Less than 1% of the administered dose is recovered in the urine in form of the parent compound. The mean elimination half-life of tenoxicam is 72 hours (range 59 to 74 hours). The total plasma clearance is 2 mL/min.

### **Linearity**

The pharmacokinetics of tenoxicam are linear in the investigated dose range of 10 to 100 mg.

### **Pharmacokinetics in special populations**

Studies in the elderly, and in patients with renal insufficiency or liver cirrhosis suggest that no dose adjustment is necessary to achieve plasma concentrations similar to those seen in healthy subjects.

Patients with rheumatic diseases and the elderly show the same kinetics profile as healthy volunteers.

Because of the high plasma protein binding of tenoxicam, caution is required when plasma albumin levels are markedly reduced (see section 4.4).

## **5.3 Preclinical safety data**

Tenoxicam showed no mutagenic, carcinogenic or teratogenic effects in animals.

---

## **6. Pharmaceutical Particulars**

---

### **6.1 List of excipients**

Tilcotil film coated tablets also contains:

- Lactose
- Maize starch
- Talc

- Magnesium stearate
- Hypromellose
- Titanium dioxide (E171)
- Iron oxide yellow (CI77492, E172).

## 6.2 *Incompatibilities*

Not applicable.

## 6.3 *Shelf life*

5 years

## 6.4 *Special precautions for storage*

Store at or below 30°C. Tilcotil is sensitive to moisture. Store in the original package.

## 6.5 *Nature and contents of container*

Blister pack. Pack-sizes of 2, 10, 30, 50 or 100 film-coated tablets.

Not all pack sizes may be marketed.

## 6.6 *Special precautions for disposal*

No special requirements.

## 7. Medicines Schedule

Prescription Medicine

## 8. Sponsor Details

Viatris Ltd  
 PO Box 11-183  
 Ellerslie  
 AUCKLAND  
[www.viatris.co.nz](http://www.viatris.co.nz)  
 Telephone 0800 168 169

## 9. Date of First Approval

18 December 1986

## 10. Date of Revision of the Text

15 April 2025

### Summary table of changes

Section Changed	Summary of New Information
2	Updates to "Excipient with known effect"  Addition of allergen declaration

4.2, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1	Minor editorial and formatting changes
4.4	Updated 'cardiovascular and/or cerebrovascular effects' section
4.5	Updated 'Acetylsalicyclate and Salicyclates' section
4.6	Addition of 'Fertility' section
4.8	Addition of 'Fixed eruption' as an unknown adverse event Updated adverse reaction reporting website
5.1	Addition of 'Clinical / Efficacy Studies' section
6.1	Removal of allergen information
-	Addition of 'Summary of table of changes' title

TILCOTIL® is a Viatris company trade mark.